Inventor · disambiguated record
Cecilia Anna Wilhelmina Geuijen
Also filed as: GEUIJEN CECILIA ANNA W · GEUIJEN CECILIA ANNA WIHELMINA · GEUIJEN CECILIA ANNA WILHELMINA
12 granted patents·14 pending applications·68 citations·filing 2004–2024
90Inventor score
Top patents by PatentIndex Score
26 records- 0196US12139548B2Antibody that binds ErbB-2 and ErbB-3MERUS NV·Filed 2022·Granted Nov 12, 2024·4 cites·20 claims
- 0295US12247078B2ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion geneMERUS NV·Filed 2024·Granted Mar 11, 2025·3 cites·20 claims
- 0394US7858086B2Binding molecules for treatment and detection of cancerCRUCELL HOLLAND BV·Filed 2005·Granted Dec 28, 2010·34 cites·3 claims
- 0490US11279770B2Antibody that binds ErbB-2 and ErbB-3MERUS NV·Filed 2015·Granted Mar 22, 2022·7 cites·17 claims
- 0587US11732043B2Antibodies that modulate a biological activity expressed by a cellMERUS NV·Filed 2018·Granted Aug 22, 2023·3 cites·22 claims
- 0686US11780925B2ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion geneMERUS NV·Filed 2018·Granted Oct 10, 2023·5 cites·15 claims
- 0785US12195551B2Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancerMERUS NV·Filed 2018·Granted Jan 14, 2025·3 cites·9 claims
- 0885US11667714B2Binding molecules that modulate a biological activity expressed by a cellMERUS NV·Filed 2018·Granted Jun 6, 2023·3 cites·48 claims
- 0983US2024158532A1Antibody that binds erbb-2 and erbb-3MERUS NV·Filed 2024·Application pending·0 cites
- 1082US11753470B2Bispecific anti PD1-anti TIM3 antibodiesMERUS NV·Filed 2018·Granted Sep 12, 2023·2 cites·14 claims
- 1181US2024158531A1Antibody that binds erbb-2 and erbb-3MERUS NV·Filed 2024·Application pending·0 cites
- 1278US2022348683A1Antibody that binds erbb-2 and erbb-3MERUS NV·Filed 2022·Application pending·0 cites
- 1378US2024199747A1Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion geneMERUS NV·Filed 2023·Application pending·0 cites
- 1476US11685786B2Binding molecules that bind CD137 and PD-L1MERUS NV·Filed 2017·Granted Jun 27, 2023·1 cites·10 claims
- 1573US2024174756A1Antibodies that bind egfr and cmetMERUS NV·Filed 2023·Application pending·0 cites
- 1672US8551488B2Binding molecules for treatment and detection of cancerGEUIJEN CECILIA ANNA WILHELMINA·Filed 2010·Granted Oct 8, 2013·3 cites·12 claims
- 1770US2023406932A1Antibodies that modulate a biological activity expressed by a cellMERUS NV·Filed 2023·Application pending·0 cites
- 1869US2024034794A1Binding molecules that modulate a biological activity expressed by a cellMERUS NV·Filed 2022·Application pending·0 cites
- 1969US2024209105A1Binding molecules that bind cd137 and pd-l1MERUS NV·Filed 2022·Application pending·0 cites
- 2065US2024218070A1FAP BINDING DOMAINS AND BISPECIFIC BINDING MOIETIES THAT BIND FAP AND TGF-ßRIIMERUS NV·Filed 2023·Application pending·0 cites
- 2159US2023159645A1Multispecific binding moieties comprising pd-1 and tgf-brii binding domainsMERUS NV·Filed 2022·Application pending·0 cites
- 2257US11773170B2Antibodies that bind EGFR and cMETMERUS NV·Filed 2018·Granted Oct 3, 2023·0 cites·16 claims
- 2355US2024118277A1Method for detecting expression or clustering of cell surface moietiesMERUS NV·Filed 2021·Application pending·0 cites
- 2454US2007287163A1Methods for Diagnosis of Acute Myeloid LeukemiaCRUCELL HOLLAND BV·Filed 2004·Application pending·0 cites
- 2551US2022127376A1Combinations of binding moieties that bind egfr, her2 and her3MERUS NV·Filed 2020·Application pending·0 cites
- 2647US2021206875A1Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumourMERUS NV·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cecilia Anna Wilhelmina Geuijen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →